FDA Panel Votes to Recommend Six Peptides for Compounding

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the list of substances that may be compounded under Section 503A, and voted against one. The votes are recommendations only. Nothing about these peptides' legal status has changed, and none has become available as a result. Here is what the panel decided and what happens next.

What the panel voted for

According to reporting from the meeting, the committee voted to recommend the following six peptides for inclusion on the 503A Bulks List:

• BPC-157
• KPV
• TB-500
• MOTS-C
• Epitalon
• Semax

It voted against recommending a seventh substance, emideltide. The votes were narrow and split, and coverage of the meeting noted that the committee's recommendations ran counter to concerns raised by the FDA's own staff about identity, quality, and safety data for these substances.

What the vote does not mean

It is easy to read "the panel voted yes" as "these peptides are legal now." That is not what happened.

• It is not a rule. An advisory committee recommends; the FDA decides separately, through formal rulemaking, whether to add a substance to the list.
• It is not binding. The FDA is free to disagree with the committee, and it has gone against advisory recommendations before.
• Nothing has changed today. All six peptides remain in Category 2 and are not currently eligible for compounding. A recommendation does not by itself change what a pharmacy may prepare.
• It is not FDA approval. Even inclusion on the 503A Bulks List, if it happens, is not the same as FDA drug approval.

What happens next

The next meaningful step would be a formal FDA action on the 503A Bulks List, published through the Federal Register. There is no confirmed timeline for that, and it could differ from the committee's recommendation. Until the FDA acts on a specific substance, its status stays the same.

Read the full context

For the background on the 503A framework, what Category 1 and Category 2 actually mean, and a running, dated log of this process as the FDA acts, see our companion explainer: the 2026 FDA peptide compounding review. For how these restrictions began, see what happened to peptides in 2023.